跳至主要内容
临床试验/CTRI/2023/05/052653
CTRI/2023/05/052653尚未招募4 期

To evaluate the efficacy of intravenous Magnesium sulfate versus intravenous Diltiazem as first line rate controlling agent in patients presenting with atrial fibrillation- A randomized control trial - MADI TRIA

Fluid research fund0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. New onset atrial fibrillation with fast ventricular rate
  • 2. Persistent atrial fibrillation with fast ventricular rate

排除标准

  • 1. Patients already on calcium channel blockers
  • 2. Indication for electrical cardioversion
  • 3. Known case of heart blocks
  • 4. Known Severe hypomagnesemia or hypermagnesemia (serum Magnesium levels < 1.2 mg/dl or > 5.0mg/dl)
  • 5. Known case of Renal failure with recent creatinine > 3.0 mg/dl
  • 6. Systolic Blood pressure < 90mmhg
  • 7. Altered mental status
  • 8. Wide complex ventricular response
  • 9. Acute myocardial infarction
  • 10. Cardiogenic shock
  • 11. Other arrhythmias
  • 12. Pregnant patients
  • 13. Acute pulmonary edema with SPO2 < 90%, PO2 < 60 mmHg

研究者

发起方
Fluid research fund

相似试验